McPherson G A, Summers R J
Br J Pharmacol. 1982 Sep;77(1):177-84. doi: 10.1111/j.1476-5381.1982.tb09284.x.
1 A comparison has been made of the alpha 1-adrenoceptor controlling gluconeogenesis in tubules from rat renal cortex and [3H]-prazosin binding in membranes prepared from the same tissue under physiological conditions. 2 In renal tubules the alpha-adrenoceptor agonists, oxymetazoline, (--)-noradrenaline, (--)-alpha-methylnoradrenaline and (--)-phenylephrine, stimulated gluconeogenesis from pyruvate. Oxymetazoline was the most potent agonist (EC50 15.7 nM) but produced only 61% of the maximum response elicited by (--)-noradrenaline. 3 The alpha-adrenoceptor antagonists, BE2254, prazosin, indoramin and phentolamine inhibited (--)-noradrenaline-mediated increases in gluconeogenesis. The alpha 1-adrenoceptor selective compounds, BE2254 and prazosin, were the most effective antagonists with KB values of 0.74 and 1.47 nM respectively. 4 [3H]-prazosin binding to membranes prepared from rat renal cortex in physiological saline at 37 degrees C was best described by a two site model. High affinity, but not low affinity sites had characteristics consistent with alpha-adrenoceptors. 5 High affinity [3H]-prazosin binding could be completely displaced by the alpha-adrenoceptor agonists, oxymetazoline, (--)-noradrenaline, (--)-phenylephrine, and (--)-alpha-methylnoradrenaline. Slope factors for the displacement curves were all significantly less than unity. The concentrations of agonists required to displace [3H]-prazosin binding were markedly higher than those required to stimulate gluconeogenesis. 6 High-affinity [3H]-prazosin binding was also displaced by the alpha-adrenoceptor antagonists, prazosin, BE2254, phentolamine and indoramin. Slope factors for the displacement curves were close to unity. Ki values calculated from the binding experiments were very similar to KB values obtained in the gluconeogenesis studies. These results suggest that in rat renal cortex the alpha 1-adrenoceptor labelled by [3H]-prazosin is probably that which stimulates gluconeogenesis.
对大鼠肾皮质肾小管中控制糖异生的α1 - 肾上腺素能受体与在生理条件下从同一组织制备的膜中[3H] - 哌唑嗪结合情况进行了比较。
在肾小管中,α - 肾上腺素能受体激动剂羟甲唑啉、( - ) - 去甲肾上腺素、( - ) - α - 甲基去甲肾上腺素和( - ) - 去氧肾上腺素刺激丙酮酸生成糖异生。羟甲唑啉是最有效的激动剂(EC50为15.7 nM),但产生的最大反应仅为( - ) - 去甲肾上腺素引发反应的61%。
α - 肾上腺素能受体拮抗剂BE2254、哌唑嗪、吲哚拉明和酚妥拉明抑制( - ) - 去甲肾上腺素介导的糖异生增加。α1 - 肾上腺素能受体选择性化合物BE2254和哌唑嗪是最有效的拮抗剂,其KB值分别为0.74和1.47 nM。
在37℃生理盐水中,[3H] - 哌唑嗪与大鼠肾皮质制备的膜结合情况最好用双位点模型描述。高亲和力位点(而非低亲和力位点)的特征与α - 肾上腺素能受体一致。
高亲和力的[3H] - 哌唑嗪结合可被α - 肾上腺素能受体激动剂羟甲唑啉、( - ) - 去甲肾上腺素、( - ) - 去氧肾上腺素和( - ) - α - 甲基去甲肾上腺素完全取代。取代曲线的斜率因子均显著小于1。取代[3H] - 哌唑嗪结合所需的激动剂浓度明显高于刺激糖异生所需的浓度。
高亲和力的[3H] - 哌唑嗪结合也可被α - 肾上腺素能受体拮抗剂哌唑嗪、BE2254、酚妥拉明和吲哚拉明取代。取代曲线的斜率因子接近1。从结合实验计算得到的Ki值与糖异生研究中获得的KB值非常相似。这些结果表明,在大鼠肾皮质中,被[3H] - 哌唑嗪标记的α1 - 肾上腺素能受体可能就是刺激糖异生的受体。